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Abstract
Cutaneous leishmaniasis has various outcomes, ranging from self-healing reddened pap-
ules to extensive open ulcerations that metastasise to secondary sites and are often resis-
tant to standard therapies. In the case of L. guyanensis (L.g), about 5–10% of all infections
result in metastatic complications.We recently showed that a cytoplasmic virus within L.g
parasites (LRV1) is able to act as a potent innate immunogen, worsening disease outcome
in a murinemodel. In this study, we investigated the immunophenotype of human patients
infected by L.g and found a significant association between the inflammatorycytokine IL-
17A, the presence of LRV1 and disease chronicity. Further, IL-17A was inversely correlated
to the protective cytokine IFN-γ. These findings were experimentally corroborated in our
murinemodel, where IL-17A produced in LRV1+ L.g infection contributed to parasite viru-
lence and dissemination in the absence of IFN-γ. Additionally, IL-17A inhibition in mice
using digoxin or SR1001, showed therapeutic promise in limiting parasite virulence. Thus,
this murinemodel of LRV1-dependent infectious metastasis validated markers of disease
chronicity in humans and elucidated the immunologic mechanism for the dissemination of
Leishmania parasites to secondary sites. Moreover, it confirms the prognostic value of
LRV1 and IL-17A detection to prevent metastatic leishmaniasis in human patients.
Author Summary
Cutaneous leishmaniasis is a neglected parasitic disease particularly problematic in the
South American tropics, where the parasites have an ability to migrate from the initial
inoculation site in a process called “infectiousmetastasis”. Despite existing for centuries,
the factors involved in parasite dissemination are largely unknown.We recently described
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that Leishmaniavirus (LRV), a virus present within some Leishmania parasites, is respon-
sible for an exacerbation of the disease outcome in mice together with treatment failure
and symptomatic relapse in human patients. In this paper we show that the expression of
the pro-inflammatory cytokine IL-17A is correlated with disease chronicity in patients
infected by LRV+ Leishmania parasites. We confirmed this finding in a unique murine
model where IL-17A was also found to play a role in LRV1-dependent infectiousmetasta-
sis. Additionally, using IL-17A as a prophylactic target, we were able to inhibit parasite
proliferation and the development of infectiousmetastasis. Thus, we identify a pathogenic
role for IL-17A in LRV1-dependent cutaneous leishmaniasis and infectiousmetastasis.
More importantly, our data suggests that in addition to LRV presence, IL-17A is a marker
of disease severity and could be a novel target to promote lesion resolution and prevent
parasite dissemination.
Introduction
Currently 5% of humanity lives at risk of Leishmania infection across 98 countries worldwide [1].
This threat is wideningwith climate change and vector spread [2] to include Southern Europe [3]
and Northern America [4]. Leishmania parasites are mostly (80%) dermotropic, infesting and
ulcerating human skin around the inoculation site of their haematophagous sand fly vector.
While most infections remain localized at this site, several of the 20+ Leishmania species have a
particular risk of infectiousmetastasis, where parasites migrate to unrelated cutaneous locations,
causing secondary lesions that are often severely inflamed, deforming surrounding tissues into
debilitating ulcerations, nodular granulomas or maculopapular rashes [5]. This may occur several
years after resolution of the initial lesion where the extreme symptomatic diversity and poor
predictability of the outcome posesmajor challenges to the diagnosis, treatment and control of
metastatic leishmaniasis in the resource-scarce environments in which it is endemic [6, 7].
Naturally occurringLeishmania-RNA-viruses (LRV) of the Totiviridae family have been
found in the cytoplasm of several parasite species [8–11]. In murine models, the dsRNA viral
genome is recognizedby host Toll-Like Receptor 3 (TLR3) [10, 12], initiating a potent innate
anti-viral inflammatory cascade. In L.g infection, we have shown that this reaction exacerbates
lesional inflammation and increases parasite survival in mice [12]. Furthermore, LRV1 was
associated to treatment failure and mucosal manifestations in humans [13–15]. Interestingly,
while the presence of LRV1 in L.g parasites is able to worsen the symptomatic outcome in our
C57BL/6 murine model, the mice ultimately heal, with no evidence of secondary lesions [16].
Indeed, C57BL/6 mice are notorious for being resistant to numerous spp. of the L. Leishmania
subgenus, such as L.major. Previously, it was shown that this resistance and susceptibility
diverge with CD4+ T-cell polarisations whereby resistance is marked by a cell-mediated TH1
reaction, while mice succumb to disease under a TH2 polarisation [17, 18]. Since then, however,
the true complexity of T-cell polarisation has been revealed, and the TH1/TH2 dichotomy in
leishmaniasis has slowly shifted from a paradigm to a paradox [19]. For instance, CL in
humans or diseasemodels other than L.major have a much more graded and heterogeneous
response, including potentially major roles for TREG, TH9 and TH17 populations [20–22]. Nev-
ertheless, metastatic CL due to L. guyanensis is not documented in mice, and consequently,
there is no simple model or information on the immunological determinants of leishmanial
metastasis with which we could design immunotherapeutic interventions to prevent and treat
this disfiguring clinical complication.
The role of the TH17 response is potentially noteworthy in hyper-inflammatory CL. Its key
cytokine, IL-17A has a reputation as the architect of numerous chronic inflammatory diseases
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such as multiple sclerosis, inflammatory bowel disease, asthma, psoriasis, rheumatoid arthritis,
contact dermatitis, systemic lupus erythrematous [23], several cancers [24] and even depres-
sion [25]. Amongst its various functions, IL-17A is well known to induce immune cell migra-
tion, recruitment and activation.
We had previously hypothesised LRV1 to be an inflammatory virulence factor leading to
infectious chronicity and metastatic leishmaniasis in humans. To test this hypothesis, we inves-
tigated the inflammatory phenotype of human patients infected by LRV1+ L.g parasites, specif-
ically in relation to the role of IL-17A and IFN-γ in chronic outcomes. These findings were
validated in murine models in which we were also able to demonstrate that LRV1-dependent
metastasis is mediated by IL-17A in a low or depleted IFN-γ environment. Finally, we demon-
strate that blocking IL-17A expression is able to prevent LRV1-dependent pathology and thus
that LRV1 and IL-17A have significant potential to guide prognosis and develop an immuno-
therapeutic approach for the treatment and prevention of this disfiguring form of the disease.
Results
IL-17A production is associated with LRV1 presence and disease
chronicity in human cutaneous leishmaniasis
To establish the clinical relevance of IL-17A in LRV1+ L.g infections, we screened 78 adult
human CL patients infected by L.g parasites in French Guiana. Patients were diagnosedwith
leishmaniasis and separated into two groups depending on the presence of LRV1. In this inves-
tigation, 30 LRV1+ L.g and 48 LRV1- L.g infected adults were studied. Selection criteria for this
cohort included HIV-negative patients who were otherwise healthy and who had not previ-
ously received anti-leishmanial treatment. Among the 78 selected patients, 14 (18%) presented
with chronic lesions that had persisted for over 5 months, whereas the remaining patients
(82%) were enrolled during the acute phase of their disease. Patients infected by LRV1+ L.g
parasites had the largest proportion of chronic lesions (8/30 patients, 27%), which was more
than double of that found in LRV1- L.g infections (6/48 patients, 12.5%) (Fig 1A). Due to the
limited group size, this observation could not be reliably tested for statistical significance.
In order to identify patterns in IL-17A secretion between acute and chronic outcomes, a
qRT-PCR was performedon tissue from intralesional biopsies. Analysis showed a significant cor-
relation between IL-17A and the presence of LRV1 as well as the outcome of chronicity (Fig 1B).
Further, immunophenotyping in patients presenting with acute disease revealed that LRV1-asso-
ciated IL-17A secretionwas inversely related to IFN-γ secretion (Fig 1C), suggesting that LRV1
detection is predictive of inflammatory responses involving a high IL-17A/IFN-γ ratio (Fig 1D).
Patient blood samples provided a larger number of lymphocytes with which we could deter-
mine the identity of IL-17A-producing cells and confirm IL-17A production at the protein
level. To this end, lymphocytes isolated from blood samples were re-stimulated ex vivowith
live L.g parasites and an ELISAwas performed on the cell-free supernatant. Similarly to the
intralesional biopsies, samples from the LRV1+ cohort had significantly increased levels of IL-
17A compared to their LRV1- counterparts (S1 Fig). Analysing the IL-17A contributions of
the CD4+ and CD4- cell populations, we found that CD4+ T cells produced the vast majority
(~80%) of LRV1-induced IL-17A in human patients (Fig 1E).
LRV1 induces IL-17A secretion in murine leishmaniasis and contributes
to LRV1-mediated disease severity
To validate whether IL-17A could be predictive of chronic inflammation, we inoculatedmice
in the hind footpads with LRV1+ or LRV1-L.g parasites. At the peak of infection, lymphocytes
LeishmaniavirusDependent Metastatic Leishmaniasis
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were isolated from lesional tissue and draining popliteal lymph nodes (LNs) and then re-stimu-
lated ex vivowith UV irradiated L.g parasites. Similarly to the human cohort, ELISA showed a
~10-fold LRV1-dependent increase of IL-17A in both lesional biopsies (Fig 2A) and draining
LNs (Fig 2B), which was abrogated in TLR3-/- mice (Fig 2D). Further analysis indicated that
the quantity of IL-17A (rather than its source) dictated LRV1 pathology (S2 Fig). To explore
the relevance of LRV1-dependent IL-17A production, we then infected IL-17A-deficient mice
with LRV1+ or LRV1-L.g parasites and found that they had a significantly reduced LRV1-me-
diated lesional swelling (Fig 2E) but to a lesser extent than seen in TLR3-/- mice (Fig 2C). IL-
17-/- mice also showed a reduced parasite burden at the peak of infection (Fig 2F), thus infer-
ring a detrimental role for LRV1-dependent IL-17A and confirming the existence of a patho-
genic TLR3-IL-17A signalling axis [26–30]. Importantly, a significant difference in lesion size
(Fig 2E) and parasite growth (Fig 2F), is visible between LRV- and LRV+ strains within the IL-
17A-/- mice, thus revealing that IL-17A is only one element of the complex pathogenesis of
LRV1.
In contrast to the human samples, the level of the protective cytokine, IFN-γ, was not signif-
icantly different between LRV1+ and LRV1-L.g infections in this self-healingmurine model of
disease (for lesions Fig 2G, and LNs Fig 2H).
LRV1-dependent infectious metastasis occurs in the absence of IFN-γ
To mimic the low IFN-γ levels seen in patients with LRV1+L.g infection, we tested whether we
could establish chronicity and metastasis in IFN-γ-deficientmice. As expected, both LRV1
+ and LRV1-L.g parasites were able to establish chronic disease in the absence of IFN-γ, how-
ever, betweenweeks 4–6, LRV1+L.g infectionmaintained a significantly higher pathology and
parasite burden compared to its LRV1-L.g counterpart in IFN-γ-/- mice (Fig 3A and 3B). Inter-
estingly, IFN-γ-/- mice infected with LRV1+L.g developedmultiple visible metastases on the
tail (and occasionally the fore-paws/snout) with highly significant differences in the number of
Fig 1. IL-17Aproduction is associated with LRV1 presence and disease chronicity in human cutaneous leishmaniasis. 78 cutaneous
leishmaniasis patients infected with L.g parasites were separated into two groups based on their LRV1 status (n = 30 LRV1+, n = 48 LRV1-). Two
furtherclinical groups could be distinguished based on the duration of the patients’ symptomatic infection: 64 acute patients (lesion historyof 0–5
months) and 14 chronic patients (lesion history of 5–12months). (A)Distribution of symptomatic cohortsamong LRV1+ and LRV1- infection. (B)
IL-17A transcriptswere measured in all biopsies by qRT-PCR. Values were calculated using theΔΔCTmethod and normalized to the average of
LRV1-L.g infection in the acute cohort. (C) IFN-γ transcriptswere measured in biopsies of acute patients by qRT-PCR and normalized as before.
(D)Previous qRT-PCR results were expressed for each individual as an IL-17A/IFN-γ ratio. (E) Lymphocytes were extracted from blood samples
of acute patients (LRV+ n = 5, LRV- n = 4) and separated into CD4+ and CD4- groups by MACS. Cells were re-stimulated ex vivo with L.g parasites
prior to IL-17A quantification by ELISA in supernatants. Data are mean +/- SEM using at least 2 technical replicates per condition. Significance
tested by an unpaired, parametric t-test and indicated as *: P<0.05, **P<0.005, ***P<0.0001.
doi:10.1371/journal.ppat.1005852.g001
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metastases between LRV1+ and LRV1- infections (Fig 3C). Eventually, LRV1-L.g infected
mice also developedmetastases to a similar level of their LRV1+ counterparts but only after an
additional 3–4 weeks of infection (S3 Fig). All metastases tested positively for parasite-specific
luciferase activity (Fig 3D). Taken together, these results illustrated that metastasis is a phe-
nomenon occurring in the absence of IFN-γ and is significantly accelerated by the presence
LRV1.
LRV1-dependent IL-17A secretion is exaggerated in the absence of
IFN-γ
It has been reported that IFN-γ signalling is inhibitory to IL-17A secretion [31–34]. Investigat-
ing LRV1-mediated IL-17A secretion in the popliteal LNs draining the primary lesions, we
Fig 2. LRV1 induces IL-17Asecretion inmurine leishmaniasis and contributes to LRV1-mediateddisease severity. Mice deficient in IL-17A
or TLR3 and theirWT controls (C57BL/6)were infected in the hind footpads with 3x106 of either LRV1+ or LRV1-L.g stationary-phase
promastigotes. At the peak of infection (4 weeks post-inoculation), cells from the footpad lesions and popliteal LNs were re-stimulated ex vivo. IL-
17A secretion inWTmice was quantified in the supernatant by ELISA in (A) intra-lesional biopsies and (B) popliteal LNs. (C)Change in footpad
swelling in TLR3-/- andWTmice was measuredweekly as a proxy for disease score. (D) IL-17A secretion from popliteal LN cells was also
compared betweenWT and TLR3-/- mice. (E)Change in footpad swelling in IL-17A-/- andWTmice was measuredweekly as a proxy for disease
score. Statistical analysis is indicated in black for comparisonbetweenWT and IL-17A-/- LRV1+ infected mice, and in grey for comparison between
IL-17A-/- LRV+ and LRV- infected mice. (F)At the peak of infection (week 4), the parasite burden of the mice depicted in (E)was quantified by in
vivo parasite luminescence, after injectingmice intra-peritoneally with luciferin. As previously for IL-17A, IFN-γ secretion in WTmice was quantified
in the supernatant of restimulated cells by ELISA in (G) intra-lesional biopsies and (H) popliteal LNs. Graphs are representative of a minimumof 3
independent experiments, using at least 5 mice per condition and presented as mean ± SEM. Significance tested by an unpaired, parametric t-test
(bar graphs) or one-way Anova (disease score), and indicated as *: P<0.05, **P<0.005, ***P<0.0001.
doi:10.1371/journal.ppat.1005852.g002
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Fig 3. LRV1-dependent infectious metastasisoccurs in the absenceof IFN-γ.Mice deficient in IFN-γ and theirWT controls (C57BL/6)were
infected in the hind footpads with LRV1+ or LRV1-L.g stationary-phase promastigotes. (A) The change in footpad swelling was measured
weekly as a proxy for disease progression. Statistical analysis is indicated for comparisons betweenWT LRV1+ infected mice in black and IFN-
γ-/- mice in grey. (B)At the peak of WT infection (week 4) in vivo parasite luminescence was determined as a measure of parasite burden. (D)At
7 weeks of infection, LRV1+L.g infected IFN-γ-/- mice developed secondary lesions in their tails which were positive for parasite luminescence.
(C) The number of secondary lesions was counted in all groups of mice. (E)At 4 weeks post infection, lymphocytes were extracted from popliteal
LeishmaniavirusDependent Metastatic Leishmaniasis
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found that IL-17A was significantly increased in the absence of IFN-γ and exaggerated in the
presence in LRV1 (Fig 3E). Further, in IFN-γ-/- mice infected with LRV1+L.g parasites, signifi-
cant induction of IL-17A was found in LNs draining the footpad (Fig 3F) and metastatic tail
lesions (Fig 3G).
IL-17Amediates LRV1-dependent metastasis in the absence of IFN-γ
Our human data suggested a direct correlation between IL-17A production, LRV1 presence
and lesion chronicity (inversely related to IFN-γ production) (Fig 1).We thus set out to deter-
mine the role of IL-17A in LRV1-mediated infectiousmetastasis in a murine model of disease.
To this end, we generated IFN-γ-/-IL-17A-/- double knockout mice (DKO) with which we
could examine IL-17A function in IFN-γ deficient environments. We confirmed the relevance
of IL-17A by infectingDKO mice. Although we could observe reduced infectionwith either
LRV1+ (Fig 4A) or LRV-L.g parasites (Fig 4B) compared to IFN-γ -/- mice, the DKO animals
rarely developedmetastasis by week 7 (Fig 4C). These results suggest that blocking IL-17A
expression could prevent LRV1-parasite dissemination to secondary lesions.
IL-17A inhibiting drugs, digoxin and SR1001, reduce LRV1-mediated
disease severity in mice
We subsequently tested whether digoxin (shown to inhibit IL-17A production [35] and possi-
bly tumour metastasis [36]) and SR1001 (described to impede the differentiation and function
of TH17 cells [35, 37]) could reduce LRV1 mediated disease severity in our murine model.
Digoxin and SR1001 treatments were commenced at the onset of visible lesional swelling (2.5
weeks post infection). The drugs were delivered systemically via intra-peritoneal injections
every second day, at concentrations previously reported to reduce IL-17A secretion in vivo. In
LRV1+L.g infected C57BL/6 mice, we found that both drugs had an effect on lesional swelling
(S4A Fig) and reduced parasite burden to levels found in IL-17A-/- mice (S4D Fig). IL-17A
secretion in draining popliteal LNs was also decreased (S4C Fig). Additionally, as expected,
there was no effect in IL-17A-/- mice (S4D and S4F Fig). We then repeated this experiment in
IFN-γ-/- mice (Fig 4D).When lesions started to appear (week 2.5), digoxin and SR1001 were
injected i.p. Although we didn’t observe a major effect on footpad swelling, such treatments sig-
nificantly blocked the development of secondary lesions in the tail (Fig 4E) and decreased IL-
17A secretion in the popliteal nodes at 4 weeks post infection (Fig 4F), and in the popliteal and
iliac lymph nodes 7 weeks post infection (Fig 4G–4H).
Discussion
L. guyanensis is one of the major parasite species plaguing populations of the Amazonian
basin.When present, its endosymbiotic virus (LRV1) acts as a potent innate immunogen capa-
ble of worsening lesional swelling in mice [12] and is correlated with first-line treatment failure,
symptomatic relapse and metastasis in humans [13, 15]. Similarly, LRV1 presence in L. brazi-
liensis was linked to treatment failure in humans [14] and exacerbated pathology in an HIV-L.
braziliensis co-infected patient [38]. Thus far, epidemiological evidence suggests that LRV1
prevalence is highly variable among Leishmania species and is concentrated in certain
LNs draining the primary lesion and then re-stimulated ex vivo. IL-17A secretionwas quantified by ELISA in cell-free supernatants. (F-G)At 7
weeks post infection, lymphocytes were extracted from (F) popliteal LNs and (F) iliac LNs drainingmetastatic lesions, and restimulated. IL-17A
productionwas quantified by ELISA as above. Graphs are representative of a minimumof 3 independent experiments, using at least 5 mice per
condition and presented as mean ± SEM. Significance tested by an unpaired, parametric t-test, (bar graphs) or one-way Anova (disease score),
and indicated as *: P<0.05, **P<0.005, ***P<0.0001.
doi:10.1371/journal.ppat.1005852.g003
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Fig 4. IL-17AmediatesLRV1-dependentmetastasis. (A-C)Mice deficient in IFN-γ-/- or IFN-γ-/- IL-17A-/- (DKO) were infected in
footpads with either (A) LRV1+ or (B) LRV1- L.g promastigotes. Footpad swelling was measuredweekly. (C) The number of secondary
lesions was counted in all groups at 7 weeks post infection. (D-H) IFN-γ-/- mice were infected in their footpads with LRV1+/- L.g
parasites. At the onset of visible lesions (2.5 weeks post infection) IFN-γ-/- mice were treated i.p with either one of the IL-17A inhibitors
every 2 days, namely Digoxin (Dig) or SR1001 (SR). (D) The change in footpad swelling was measuredweekly. (E)At 7 weeks post
infection, the number of secondary lesions was counted in all groups of treatedmice. (F)At week 4 post infection, popliteal lymph node
cells frommice presented in (D), were restimulated for 72h in vitrowith UV inactivated L.g parasites. IL-17A production in culture
supernatants was measured by ELISA. After 7 weeks, lymphocytes from (G) popliteal and (H) iliac lymph nodes were also restimulated
in vitro in order to quantify IL-17A production by ELISA. Graphs are representative of a minimumof 2 independent experiments, using
at least 5 mice per condition and represented as mean ± SEM. Significance is tested by one-way Anova (disease score) or an
unpaired, parametric t-test (bar graphs) and indicated as *: P<0.05, **P<0.005, ***P<0.0001.
doi:10.1371/journal.ppat.1005852.g004
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geographic locations [13, 39, 40]. While LRV1 is present in some major metastatic strains of
Leishmania and has been linked to metastasis in humans [15], no large-scale epidemiological
data exist to assess the true correlation between LRV presence and metastatic leishmaniasis.
For instance, LRV has not yet been detected in the metastatic strains of L. panamensis and a
small-scale study has shown that metastasis is not exclusively associated with LRV presence in
L. braziliensis [41]. Thus suggesting that infectiousmetastasis is a complex multifactorial pro-
cess, in which parasite phylogeny, host immunocompetence, co-infecting pathogens, such hel-
minths or viruses [42, 43] and environmental influencesmay also play a role [5].
Little is known about the immunology of L.g infections and their metastatic behaviour as
few experimental studies have been performed on these parasites. While the presence of LRV1
is able to induce visible disease in C57BL/6 mice, it is nevertheless self-healing, where swelling
and parasite load dissipates over the course of 7 weeks [12]. The innate resistance of C57BL/6
mice to most Leishmania strains is often attributed to a TH1 bias, in which abundant IFN-γ is
able to activate a parasitotoxic respiratory burst in macrophages. Equally, however, excessive
TH1 signalling has been blamed for the destructive inflammatory effects in some chronic leish-
maniases [44–46]. Thus, many reports have describedTH1 to have a “window of protective
opportunity”, being damaging in excess and permissive to parasite proliferation in absence
(reviewed in [47]). Our study on human patients found that LRV1+ L.g infections had a signifi-
cantly reduced level of IFN-γ compared to LRV1- L.g. Interestingly, the opposite trend was
found with the inflammatory cytokine, IL-17A, indicating that LRV1 detection could be pre-
dictive for this inflammatory imbalance in human CL. Supporting this hypothesis was that
both LRV1 and IL-17A significantly correlated to lesion chronicity. We were able to validate
these observations in a C57BL/6 murine model of disease, where we also found that IL-17A
contributed to LRV1-mediated pathology and parasite survival. A significant observation in
the IL-17A-/- murine model was that LRV1-mediated pathology was not completely abrogated
in the absence of IL-17A, thus demonstrating that IL-17A is only part of the complex patho-
genic inflammatory response induced by LRV.
Indeed, a recent publication showed that IL-17A worsened CL caused by L.major in a sus-
ceptible BALB/c murine model that is notorious for its reduced level of IFN-γ [48]. This find-
ing could also be reproduced in L.major infectedC57BL/6 mice but only in the absence of IL-
10 and especially in conditions of reduced IFN-γ signalling [49]. The destructive potential of
IL-17A in leishmaniasis has also been corroborated in human disease, where IL-17A-mediated
cell infiltration was linked with tissue damage in human mucosal leishmaniasis caused by L.
braziliensis parasites [50]. The variable roles of IL-17A across murine models might be linked
to differences in the type and potency of concomitant IFN-γ signalling. Interestingly, in the
murine models of L. braziliensis and L. amazonensis, the infections were linked with IL-17A-
producing T-cells. However, progressive L. amazonensis did so in an IFN-γ low environment
[51] while submissive L. braziliensis parasites were associated with IFN-γ high CD4+ T cells
[52], thus indicating that IFN-γmight control the pathogenicity of IL-17A in Neotropical leish-
maniases. Unfortunately, however, these cytokines were not tested for their role in infectious
metastasis and the LRV-status of the parasites used in the above studies remains unknown.
Our observation that IFN-γ levels are suppressed during LRV1+ L.g infection in human
patients may corroborate our previous finding where suppressive regulatory T cells were dem-
onstrated to accumulate in CL lesions of the Neotropics, leading to a suppression of IFN-γ and
exacerbated disease outcome [53]. As IFN-γ levels were unchanged between LRV1+ and
LRV1- L.g infections in our C57BL/6 murine model, we hypothesised that IFN-γwas responsi-
ble for disease resolution. Indeed, infection in an IFN-γ-/- mouse resulted in chronic disease in
both LRV1+ and LRV1- L.g infections. However, only IFN-γ-/- mice infected with LRV1+ L.g
parasites developed secondary lesions at 7 weeks post infection.On the other hand, LRV1- L.g
LeishmaniavirusDependent Metastatic Leishmaniasis
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infection required an additional 3–4 weeks to develop the same level of metastatic disease.
Thus, this is the first study to describe that LRV1 is associated with accelerated infectious
metastasis in murine cutaneous leishmaniasis. The pattern of metastasis in this murine model
was anatomically predictable, appearing 95% of the time in the experimentally accessible and
easily visible cutaneous tissue of the tail (occasionally, lesions were also found on the forepaw
or snout). A common feature of these regions is the slightly cooler skin temperatures and fewer
hair follicles, allowing us to speculate that either the parasites seek out cooler skin regions, or
that lesions occur in regions frequently exposed to physical irritation such as is observed in
humans [54], and in an experimentalmurine model of distal skin trauma [55].
In an effort to screen for immunological determinants of metastatic leishmaniasis, we used
the IFN-γ-/- mouse as a model of infectiousmetastasis. Similarly to the inverse correlation we
observed in the human cohort, IL-17A secretionwas exaggerated in the absence of IFN-γ. Fur-
ther, removing IL-17A from our metastatic model significantly delayed the incidence of infec-
tious metastasis.While it is clear that IL-17A is secreted in response to a variety of Leishmania
species, the molecules triggering this response have not yet been described.The Paleotropic L.
major species is generally LRV-negative (with one exception [56]). Considering that IL-17A has
been shown to enhance disease severity in these assumedly LRV-negative L.major infections (in
both BALB/c [48] and C57BL/6 [49] mice), there are certainly LRV1-independent triggers of IL-
17A secretion. In our model, IL-17A secretion is also detected in lesions and draining LNs of
LRV1- L.g infection but is significantly up-regulated in response to LRV1. Thus, we expect that
an IL-17A amplificationmechanism exists downstream from the LRV1-induced anti-viral signal-
ling pathway of TLR3 [12]. Interestingly, previous reports support the existence of a TLR3-IL-
17A signalling axis [26, 28]. The connection betweenTLR3 and IL-17A could also rely on the
micro-RNA (miR)-155 [57]. In fact, miR-155 is thought to be essential for the development and
maintenance of TH17 cells, where miR-155 interacts with TH17 transcription factors, STAT3
[58] and SOCS1 [59]. Further, miR-155-/- TH17 cells are hypo-responsive to a key maintenance
cytokine, IL-23 [60]. Together, these observations suggest that miR-155 could play an important
role in IL-17A-related pathology in CL and deserves further investigation.
A wide variety of cells are able to produce IL-17A. Our analysis of human blood samples
revealed the vast majority of LRV1-associated IL-17A to be produced by CD4+ T cells. How-
ever, further investigation in our murine model revealed the source of IL-17A to be more het-
erogeneous. Irrespective of the LRV-status of the infecting parasite, the majority of IL-17A-
producing cells were CD3+ T cells carrying the classic TCRαβ: CD4+, CD8+ and also T cells
double negative (DN) for CD4 and CD8. The former cell type has been recently appreciated as
an important determinant of pathology in CL [61], where they have been described as hyper-
activated inflammatory cells [62]. Further, double negative T cells are already well known for
their ability to produce pathological IL-17A in the autoimmune disease systemic lupus erythre-
matous [63]. IL-17A was also produced by a significant proportion of CD3+ T cells hosting
TCRγδ, however, testing in a deficient mouse model ruled out this population as a determinant
of LRV1-mediated pathology (S5 Fig).
Having established the pathogenic role of IL-17A in LRV1-mediated pathology, we explored
whether depleting the cytokine in our murine model could have therapeutic benefits.While IL-
17A neutralizing antibodies are available, this is not an economically feasible treatment option
for the vast majority of leishmaniasis patients. Thus, we explored less expensive IL-17A block-
ing options, namely digoxin and its derivative, SR1001 which are able to inhibit the differentia-
tion and functioning of TH17 cells by inducing inhibitory conformational changes in two key
IL-17A transcription factors, RORα and RORγt [35, 37]. It was previously shown that daily
intra-peritoneal doses of these drugs were able to reduce the clinical severity of a murine model
of IL-17A-mediated experimental autoimmune encephalomyelitis (EAE) [35, 37]. Similarly, by
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treating our C57BL/6 murine model of leishmaniasis with digoxin and SR1001, we were able to
significantly decrease IL-17A production in draining LNs resulting in a reduction of disease
severity that reached levels comparable to that of the IL-17A-/- model. Interestingly similar
treatment in IFN-γ-/- mouse demonstrated a crucial role for IL-17A downstream pathways in
parasite dissemination to secondary lesions. Thus far, our testing in IL-17A-/- and IFN-γ-/- IL-
17A-/- mice showed no additional effects of digoxin or SR1001 on parasite burden, indicating
that both drugs do not have IL-17A independent parasitotoxic activities in vivo. Further, as IL-
17A has been shown to be pathologic in other forms of leishmaniasis, these drugsmay hold
therapeutic potential across a broader range of leishmanial species.
In conclusion, this report describes the first murine model of LRV1-mediated cutaneous
leishmanial metastasis.We show that this process is mediated by IL-17A in the absence of
IFN-γ and that IL-17A-inhibiting drugs are able to reduce LRV1-associated pathology. These
results confirm our observations in a human cohort, where IL-17A production was linked to
both the presence of LRV1 and disease chronicity.
Taken together, these results indicate that the detection of LRV1 or IL-17A in leishmaniasis
has significant prognostic value and could be used to guide the therapeutic approach for the
prevention and treatment of metastatic leishmaniasis.
Methods
Human patient selection and sample collection
Patients were received at the Centre Hospitalier Andrée Rosemon in Cayenne, French Guiana.
Inclusion criteria selected newly diagnosed adult patients infected with L.g who had never pre-
viously received anti-leishmanials. Lesional history ranged from 1-12 months. HIV testing was
conducted on an opt-in basis, and was a requirement for pre-selection, where only HIV-nega-
tive patients were included in order to maintain immunocompetencewithin the cohort. Simi-
larly, a patient history revealing other autoimmune or infectious diseases was considered an
exclusion criterion. Samples collected included: serous dermal fluid from the lesional border
(lesional exudate), blood and a 2 mm intra-lesional punch biopsy. In total, 78 patient samples
fitted these criteria (30 LRV1+ and 48 LRV1-).
Leishmaniasis diagnostics and parasite phenotyping
Following local guidelines and standard protocol, diagnosis of leishmaniasis was based on
microscopic analysis of lesional exudate by May-Grünwald Giemsa staining.Microscopy
results were confirmed by in vitro parasite culture, where Schneider’s culture medium
(describedbelow) was inoculatedwith a segment of the 2 mm intra-lesional punch biopsy. Par-
asite cultures could then be typed by phylogenic RFLP-PCR analysis (based on a conserved iso-
enzyme polymorphism as previously described [64]).
In vitro parasite culture. The two isogenic clones of L.g infected with, or depleted of
LRV1 (termed LRV1+ or LRV1- respectively), used in this study were described and character-
ized previously [65]. Briefly, these lines were derived from the LRV1+ parent strain, L.gM4147
(MHOM/BR/75/M4147) or an LRV1-null derivative [66]. The parasites express similar levels
of a firefly luciferase (5x107 photons/sec/106 parasites) from a LUC gene integrated stably into
the small subunit gene of the ribosomal RNA locus.
Parasites were cultured in vitro as promastigotes at 26°C in freshly prepared Schneider’s
insect medium (Sigma) supplemented with 10% heat-inactivated foetal bovine serum (PAA),
10mMHEPES and 50U/ml penicillin/streptomycin (Animed), 0.6 mg/L biopterin and 5 mg/L
hemin (Sigma-Aldrich). Each passage yielded infectiousmetacyclic promastigotes after 6 days
and stocks were kept for no longer than 5 passages.
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LRV1 detection in parasite isolates and biopsies. Parasite cultures were tested for LRV1
by qRT-PCR performed on both parasite cultures and lesional material using primers specific
to a conservedLRV1 sequence (listed below). Briefly, total RNA was isolated using the RNeasy
minikit (Qiagen) as previously described [67]. cDNA synthesis was performed on total RNA
by using a first-strand cDNA synthesis kit (Superscript III, Invitrogen). qRT-PCR was carried
out on a 7300 Real Time System (Applied Biosystems). To verify results and control for RNA
contamination, parasite cultures were randomly selected and re-tested by various immuno-
detection techniques as previously described [11]. Briefly, an antibody recognizing dsRNA irre-
spective of its underlying sequence (J2- English & Scientific Consulting) was used for dot-blot,
ELISA and immunofluorescence detection. LRV1 presence was confirmed relative to the LRV1
+ L.g (MHOM/BR/75/M4147) and the LRV1- L. panamensis (MHOM/PA/1971/LS94) para-
sites, used respectively as positive and negative controls.
Cytokine quantification in human lesion biopsies and blood samples
Lesional tissue. Total RNA was isolated from lesional tissue similarly to the LRV1
qRT-PCR above. qRT-PCR was then performed on cDNA, testing for il17a and ifnγ transcripts
(primers listed below).
Blood. Leukocyteswere isolated from human blood in a Ficoll (Sigma-Aldrich) density
gradient according to manufacturer’s instruction.A part of these cells were separated into CD4
+ and CD4- compartments by magnet-activated cell sorting (MACs) using a positive selection
CD4+ cell kit (Miltenyi Biotec). Selected cells were re-stimulated at a concentration of 1x106
cells/ml for 5 days in RPMI. To these sorted blood cells, a mixture of LRV+ L.g parasites
(1x106/ml) and antigen presenting cells (1x105/ml,) was added and incubated during 5 days at
37°C. Antigen presenting cells were autologous PBMCs (treated with 1μg/ml of mitomycin C
during 30 min at 37°C).
Cell-free supernatants were then submitted to ELISA testing for IL-17A and IFN-γ quantifi-
cation (eBioscience).
Mouse facility, breeding and infection
All mice were bred in a specific pathogen-free housing facility at the University of Lausanne,
Switzerland and backcrossed at least 10 times onto a C57BL/6 genetic background (purchased
fromHarlan Laboratories, Netherlands). The IFN-γ-/- strain was purchased from Jackson labo-
ratories, while IL-17A-/- mice were generated by Prof. Y. Iwakura at the University of Tokyo,
Japan [68]. These two strains were crossed to make a double knockout of IFN-γ -/-IL-17A-/-
(DKO).
Age-matched (6–8 week old) female mice were infected in the hind footpads with 3x106 sta-
tionary phase L.g promastigotes from either the LRV1+ or LRV1- strains. Change in footpad
swelling was measured weekly using a Vernier caliper as a proxy for disease score. Secondary
lesions in all immunocompromisedmice caused no discernable distress to the animals. All
mice received constant pain medication (1g/L Dalfalgan diluted in drinkingwater) during the
second half of their infection.However, swelling in the primary footpad lesions in LRV1+ L.g
infected immunocompromisedmice, posed an ethical limitation of 7 weeks. LRV1- L.g infected
immunocompromisedmice reached this ethical limit approximately 3–4 weeks later.
Parasite quantificationby luminescence
At the peak of infection (week 4/5) and at the onset of visible infectiousmetastasis (week 7/8),
parasite burden was quantified using in vivo imaging able to detect luminescence emitted by
luciferase-transfectedparasites. Briefly, mice were injected intra-peritoneally with D-Luciferin
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sodium salt (Regis technologies) prepared in PBS at a final concentration of 150 mg/kg. After a
10 min incubation,mice were anesthetized by continuous gas anaesthesia and imaged using a
Xenogen Lumina II imaging system (IVIS, 10 min exposure time). Total photon flux over the
primary lesions or length of the tail was assessed using the associated software (Living Image).
Parasite isolation and culture frommetastatic lesions
Biopsies were taken from visible metastases in the tails, forepaws and snouts of affectedmice 7
weeks post infection. Biopsy material was gently homogenized using a sterile tissue culture pes-
tle and mortar. The lesion homogenate was then used to inoculate 3 culture dishes of complete
Schneider’s insect medium. The presence of Leishmania parasites was confirmed by micros-
copy after 5 days of culture.
Digoxin and SR1001 in vivo treatment protocol
Digoxin (Carbosynth) was diluted in PBS and SR1001 (Sigma-Aldrich)was dissolved in 100%
DMSO before being diluted in PBS as previously described [37]. The final concentration of
DMSO was 1.5%, which was used in the preparation of the vehicle control. At the onset of visi-
bly swollen lesions (~2 weeks post inoculation),mice were injected intra-peritoneally every sec-
ond day with 20 mg/kg (1250 μM) SR1001, or 40 μg/mouse of Digoxin, or vehicle control.
Treatment continued for 3 weeks in wild type C57BL/6 mice (until week 5 of infection) and for
5–6 weeks in IFN-γ-/- and IFN-γ-/- IL-17A-/- mice (until mice were humanely euthanized).
Quantificationof cytokine secretion in draining LNs
At the same time points as parasite quantification, lymphocytes were isolated from the LNs
draining the primary lesions (popliteal) and those draining the metastatic tail lesions (iliac).
Cells (5x106/ml) were stimulated with UV-irradiated L.g LRV1+ and LRV1- promastigotes
(1x106/ml) in complete medium:DMEM (Gibco), supplemented with 10% heat-inactivated
foetal bovine serum (FBS), 1% penicillin/streptomycin and 1% HEPES (Sigma-Aldrich). After
72 hours, various cytokines (IFN-γ, IL-17A, IL-17F and IL-17A/F) were quantified in cell-free
culture supernatants by ELISA (eBioscience) following the manufacturer’s protocol.
Flow cytometryanalysis of draining lymph nodes
Lymphocytes isolated from draining LNs (described above) were treated with 50 ng/ml PMA
and 3 μg/ml ionomycin in the presence of Brefeldin-A (10 μg/ml, Sigma) for 4 h at 37°C. Cells
were prepared for staining with fluorescent antibodies by blocking non-specific antibody bind-
ing sites using an FcR blocking reagent (Miltenyi Biotec). Extracellular antigens were then
stained with fluorescently labelled antibodies against CD3, CD4, CD8, CD19, CD49, TCRαβ
and TCRγδ according to manufacturer’s instruction (eBioscience). Cells were then prepared
for intracellular staining using an intracellular fixation and permeabilization buffer set
(eBioscience) before adding intracellular antibodies against IL-17A and IFN-γ according to
manufacturer’s instruction (eBioscience).Data was acquired on a FACSCalibur flow cytometer
(BectonDickinson) and analyzed with FlowJo software (TreeStar).
Primer sequences












actin (human): Hs 99999903-m1
The parameters for 7300 Real Time System were set to 10min at 95°C followed by 40 cycles
(15 sec at 95°C and 1 min at 60°C).
Statistics
Statistical significancewas determined using an unpaired parametric t-test (for single-point
analysis on bar-graphs) or a one-way Anova (x/y disease curves) as calculated by GraphPad
software (Prism v5). Significancewas recognizedwhen p 0.05 and represented in three ranks
namely : p 0.05, : p 0.01 and : p 0.001.
Ethics statement
Human sample collection. Human samples were extracted from 78 adult patients
enrolled into the study following written informed consent at the Centre Hospitalier Andrée
Rosemon in Cayenne, French Guiana following the hospital regulations (http://www.ch-
cayenne.net/Droits-et-Devoirs.html). Ethical approval for this study was granted on the
authority of the “Comité consultatif sur le traitement de l'information en matière de recherche”
(DR-2011-291, 911217).
Animal experimentation. All animal protocols in this publication were approved by the
Swiss Federal Veterinary Office (SFVO), under the authorization numbers 2113.1 and 2113.2.
Animal handling and experimental procedures were undertakenwith strict adherence to ethi-
cal guidelines set out by the SFVO and under inspection by the Department of Security and
Environment of the State of Vaud, Switzerland. All mouse genotypes holding the risk for devel-
oping metastatic cutaneous lesions on the tail were treated prophylactically with pain medica-
tion (1g/L Dalfalgan diluted in drinkingwater) and showed no signs of discomfort under these
conditions.
Supporting Information
S1 Fig. Production of IL17-A by PBMCs in patients infectedwith LRV1+ and LRV1- L.
guyanensis.PBMCs (106/ml) from subjects infected with LRV1+ (n = 6) or LRV1- (n = 6) L.g
were restimulated ex vivo using live LRV1+L.g promastigotes (106/ml). After 5 days, IL-17A
production was analyzed by ELISA in the culture supernatant. Data are mean +/- SEM using at
least 2 technical replicates per condition. Significance tested by an unpaired, parametric t-test
and indicated as : P<0.05, P<0.005, P<0.0001
(TIF)
S2 Fig. LRV1-dependent IL-17A secretion is produced by a variety of cell types.WT
C57BL/6 mice were infected in the hind footpads with either LRV1+ or LRV1-L.g stationary-
phase promastigotes. At the peak of infection (4 weeks), lymphocytes were extracted from pop-
liteal LNs and prepared for intracellular cytokine flow cytometry. Briefly, cells were re-stimu-
lated ex vivowith PMA/ionomycin in the presence of brefeldin-A. Extracellular antigens were
then stained to mark the following cell types: T cells (CD3+), as well as their major lineages
(CD4+ and CD8+) and receptor subtypes (TCRαβ and TCRγδ); B cells were marked using
anti-CD19, while anti-CD49b was used as a pan-NK cell marker. Stained cells were fixed and
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permeabilized in preparation for intracellular staining of IL-17A and IFN-γ. The upper panel
(A to F) shows pLN cells from LRV1+L.g infectedWTmice while the lower panel (G to L)
shows cells from LRV1-L.g infectedWTmice. L is a representative graph for the isotype con-
trol of intracellular IL-17A staining. Graphs are representative of a minimum of 3 independent
experiments, using at least 5 mice per condition and a minimum of 1x105 events per plot. Plots
are representative of the gated populations indicated at the top of each graph. The position of
each gate is indicated as a black square.
(TIF)
S3 Fig. Metastatic score in IFN-γ -/- mice.Mice deficient in IFN-γwere infected in the hind
footpads with LRV1+ or LRV1-L.g stationary-phase promastigotes. The number of secondary
lesions in the tail were counted once a week from the onset of metastasis until reaching the eth-
ical limit of the experiment. Graphs are representative of a minimum of 3 independent experi-
ments, using at least 5 mice per condition and presented as mean ± SEM. Significance is tested
by an unpaired, parametric t-test and indicated as : P<0.05, P<0.005, P<0.0001.
(TIF)
S4 Fig. IL-17A inhibiting drugs (Digoxin and SR1001) reduce disease phenotype in C57BL/
6 mice. (A-E) IL-17A-/- and theirWT controls (C57BL/6) were infected in the hind footpads
with LRV1+ L.g stationary-phase promastigotes. At the onset of visible disease (2 weeks post
inoculation)mice were treated with Digoxin (40 μg/mouse prepared in PBS) or SR1001 (dis-
solved in 1.5% DMSO and PBS to a final concentration of 20 mg/kg) by intra-peritoneal injec-
tions every second day for 3 weeks. Footpad swelling was measured weekly as a proxy for
disease progression in (A)WT and (D) IL-17A-/- mice. Significance is depicted for compari-
sons between SR1001-treated or Digoxin treated mice and control groups. At the end of the
treatment (week 5) in vivo parasite luminescencewas determined as a measure of parasite bur-
den in (B)WT and (E) IL-17A-/- mice. (C)At week 7 post infection, lymphocytes were exacted
from popliteal LNs of WTmice infected with LRV1+ L.gmice and then re-stimulated ex vivo
with UV inactivated LRV1+ L.g parasites. IL-17A was then measured in cell-free supernatants
by ELISA. (F-G) IL-17A-/- IFN-γ-/- mice were infected in the hind footpads with LRV1+ L.g
stationary-phase promastigotes and treated from week 2.5 to week 7 with Digoxin or SR1001
as mentioned above. (F) Footpad swelling was monitored weekly as a proxy for disease pro-
gression. At the peak of infection (week 4), (G) parasite burden was quantified by in vivo para-
site luminescence, after injectingmice intra-peritoneally with luciferin. (H)An enumeration of
secondarymetastatic lesions in the tail at week 7. Graphs are representative of a minimum of 3
independent experiments, using at least 5 mice per condition and presented as mean +/- SEM.
Significance is tested by one-way Anova (disease score) or an unpaired, parametric t-test (bar
graph) and indicated as : P<0.05, P<0.005, P<0.0001.
(TIF)
S5 Fig. Absence of TCRγδ T cells does not impair the course of infection.Mice deficient in
TCRδ and theirWT controls (C57BL/6) were infected in the hind footpads with 3x106 of either
LRV1+ or LRV1-L.g stationary-phase promastigotes. (A)Change in footpad swelling in
TCRγδ andWTmice was measured weekly as a proxy for disease score. (B)At the peak of
infection, the parasite burden in these mice was quantified by in vivo parasite luminescence.
Graphs are representative of a minimum of 3 independent experiments, using at least 5 mice
per condition and presented as mean ± SEM. Significance tested by an unpaired, parametric
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